Zhuangli Tang

Zhuangli Tang

Auto-generated profile, based on publicly available information

Zhuangli Tang

Department of Dermatology, Second Affiliated Hospital Zhejiang University School of Medicine Hangzhou China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 January 2024 in Frontiers in Immunology
Verified
Journal Article
Open access
QWQi Wang
Qi Wang
HCHuali Cao
Huali Cao
XZXuetong Zhang
Xuetong Zhang
HWHuifeng Wu
Huifeng Wu
ZTZhuangli Tang
Zhuangli Tang
Introduction: Apalutamide is a novel agent for castration-resistant prostate cancer while skin rashes are the most common untoward reactions. Up to now, most of the reported dermatologic adverse events (dAEs) allocated to mild and moderate with a fair prognosis. Herein, we report a case series of severe dAEs in China caused by apalutamide.Case presentation: The four patients all developed severe and lethal drug eruptions including Stevens-Johnson syndrome and toxic epidermal necrolysis with a mean incubation period of 40 days. On the basis of the medical condition, all the patients were suggested to withdraw apalutamide and three of them recovered. Of note, attempts of rechallenges of apalutamide may be fatal.Discussion: The incidence of dAEs in previously conducted clinical trials exceeded 20%, with maculopapular rashes being the most common feature. However, the incidence and severity varied in different geographic regions and ethnicities. Inadequate attention was paid to severe cutaneous adverse reactions. Long latency may easily lead to the misdiagnosis of dAEs, and immediate withdrawal of apalutamide is the cornerstone of therapies.Conclusion: Special and adequate attention should be paid to apalutamide-attributed severe cutaneous adverse effects. Besides, the prognosis of severe drug eruptions may be disappointing, and in-time withdrawal is vital.

27 May 2024 in Seminars in Arthritis and Rheumatism
Verified
Journal Article
Open access
KYKunze Yu
Kunze Yu
TWTianxiang Wang
Tianxiang Wang
DADadao An
Dadao An
XLXiawei Li
Xiawei Li
ZTZhuangli Tang
Zhuangli Tang
Drug-induced dermatomyositis (DIDM) is a rare and underestimated variant of dermatomyositis (DM) characterized by muscle damage and skin rash and related to certain drug exposure. The spectrum of drugs causing DIDM has evolved over time, originally implicating hydroxyurea, penicillamine, and statins as causative agents. Tumor necrosis factor α inhibitors and immune checkpoint inhibitors have also been associated with such conditions. To bridge the gap between current literature and clinical practice, and therefore guide clinicians, we conducted a comprehensive review of English literature from Pubmed, EMBASE, and MEDLINE. Our analysis included demographic data, clinical features, laboratory findings, therapeutic outcomes, and extant research pertaining to the probable pathogenesis of DIDM induced by various drugs. Furthermore, we categorized the drugs involved in DIDM cases into biologics and traditional agents for subsequent statistical analysis. Over time, there has been a gradual accumulation of reported DIDM cases. A total of 69 published DIDM cases were documented in our study, among which 33 should be attributed to biologics and the remaining 36 to traditional drugs. Interestingly, 41 of all DIDM cases had a previous history of malignancies. Additionally, DIDM cases exhibited similar cutaneous and muscular manifestations to classic DM, with the exception of cases induced by hydroxyurea, which did not entail muscle damage. Positive antinuclear antibodies and anti-TIF1-γ autoantibodies have been predominantly observed in biologics-induced cases, while positive anti-TIF1-γ antibodies were merely reported in the cases that were primarily diagnosed with malignant diseases and exposed to ICIs afterwards. Anti-TIF1-γ antibodies may potentially serve as a red flag in the identification of co-existing malignant diseases in DM patients. We also provided a comprehensive summary and exploration of potential mechanisms lying behind drug-induced dermatomyositis. In conclusion, our review consolidates the current literature on DIDM, highlighting the evolving spectrum of medications and elucidating the differences in clinical manifestations, laboratory findings, and underlying mechanisms.

1 September 2025 in Journal of the American Academy of Dermatology
Verified
Journal Article
Closed access
PCPeng-Yu Chen
Peng-Yu Chen
JJJing Jing
Jing Jing
YHYuan-Yu Hong
Yuan-Yu Hong
JLJue-Xing Li
Jue-Xing Li
HZHeng Zhang
Heng Zhang
SCSui-Qing Cai
Sui-Qing Cai

20 February 2025 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
QWQi Wang
Qi Wang
ZRZhao-Ting Ren
Zhao-Ting Ren
HWHui-Feng Wu
Hui-Feng Wu
HGHao-Chen Gu
Hao-Chen Gu
XLXia-Wei Li
Xia-Wei Li
ZTZhuang-Li Tang
Zhuang-Li Tang
Background: Apalutamide, an androgen receptor inhibitor, has shown good efficacy in treating prostate cancer (PCa). However, dermatological adverse events (dAEs) are common and threatening, and relevant studies in China are limited.Methods: This was a retrospective, single-center analysis. We included PCa patients who were hospitalized and received apalutamide treatment at one comprehensive hospital in eastern China from August 2020 to March 2023. These patients were categorized into two groups for comparative analysis: those with (dAEs+) and without dAEs (dAEs–) based on the presence or absence of rash or itching following apalutamide administration. Demographics, PCa clinical and treatment data were extracted from the EMRS. The clinical features of dAEs were collected through follow-up calls.Results: Our study enrolled 90 individuals with an overall dAEs incidence of 50.0%. All dAEs occurred within one year following apalutamide use. Over half of dAEs+ patients suffered from pruritus, erythema or papules, and the dAEs were predominantly mild to moderate. Higher PSA levels were found in patients with dAEs.Conclusions: Apalutamide-associated dAEs are common in the Chinese population, among which the majority are mild to moderate, with pruritus, erythema, and papules ranking as the most prevalent symptoms. Elevated PSA levels were documented in patients with dAEs.

26 October 2024 in The Journal of Dermatology
Verified
Journal Article
Closed access
PCPeng‐Yu Chen
Peng‐Yu Chen
YHYuan‐Yu Hong
Yuan‐Yu Hong
HNHuiTing New
HuiTing New
ZTZhuang‐Li Tang
Zhuang‐Li Tang
SCSui‐Qing Cai
Sui‐Qing Cai

19 January 2025 in Journal of the American Academy of Dermatology
Verified
Journal Article
Closed access
PCPeng-Yu Chen
Peng-Yu Chen
SCSui-Qing Cai
Sui-Qing Cai
ZTZhuang-Li Tang
Zhuang-Li Tang